louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00725660: Pre-Eclampsia Prediction By Doppler Screening Of Uterine Arteries And Angiogenic Factors In Second Trimester Of Pregnancy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pregnancy
Pre Eclampsia
Keywords: pre eclampsia
doppler
uterine
arteries
angiogenic
factors
Lead sponsor: Shaare Zedek Medical Center
Sponsor class: OTHER
First posted: 2008-07-30
Enrollment: 3000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination, in Jerusalem, Israel.

Brief summary: BACKGROUND: Pre-eclampsia complicates about 2% of pregnancies. It accounts for at least 50 000 maternal deaths per year worldwide and is the second most common cause of maternal death in the developing world. Also, Pre-eclampsia is the commonest cause of iatrogenic prematurity, It frequently coexists with intrauterine growth restriction (IUGR) and placental abruption, other important causes of adverse prenatal outcome.

There have been many studies investigating whether the disease can be prevented. In order to achieve this, one needs to be able to identify firstly those women that are at highest risk of the disease.

Early studies showed that impedance to flow in the uterine arteries decreases with gestation in normal pregnancies, while in pregnancies with established pre-eclampsia or IUGR the impedance is increased.

These observations led to a number of screening studies in the second trimester, which assessed if it is possible to predict those pregnancies destined to have complications of impaired placentation. These studies showed that women with increased impedance to uterine artery blood flow have an increased risk of developing pre-eclampsia, and detection can be further increased by using angiogenic factors (That are involved in the pathogenesis of Pre- eclampsia and could be useful for early prediction of the disease: VEGF, PIGF, PP13, sFLT1) in combination with uterine arteries Doppler study in the second trimester.

METHODS: In this study we would like to add uterine arteries Doppler to the early routine detailed ultrasound examination (14-16 weeks), in 3000 women in Jerusalem. in addition we would like to check angiogenic factors from the serum blood taken for the routine triple test in these women (16-18 weeks).pregnancy outcome would be collected after labour from the medical centers participating in this research.


Eligibility criteria: Inclusion Criteria:

* pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination, in Jerusalem, Israel

Exclusion Criteria:

* none

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
References:
Clinical trial NCT00232960: Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
Official title: Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Early Stages Oral and Oropharyngeal Squamous Cell Carcinomas: A Prospective Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Oral Cancer
Oropharynx Cancer
Keywords: oral and oropharynx carcinoma
surgery
postoperative radiotherapy
molecular analysis
microsatellite instability
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
Collaborators: name: Tumor Study Group Head and Neck
First posted: 2005-10-05
Enrollment: 310
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: There is no consensus on the indication of postoperative radiotherapy for early stages oral and oropharyngeal squamous cell carcinoma with complete pathological resection and no neck node metastasis, but most of the institutions do not give any post-operative treatment. Loco-regional control rates range between 80-85% at five years. Surgical margins molecular analysis for microsatellite instability (MSI) marker could help to select the high-risk patients who should receive postoperative radiotherapy. We expect to include 120 patients in five years and have 60 informative tumors for MSI marker. Patients with positive molecular margins will receive postoperative radiotherapy (50 Gy). Patients with negative molecular margins will not receive radiotherapy.


Eligibility criteria: Inclusion Criteria:

* Oral and oropharynx (exclusion vallecula) squamous cell carcinoma
* T1 or T2
* unique, untreated tumor
* N0 or nodes \<3cm
* complete pathological resection
* no perineural spread, vascular emboli \<5
* pN0 or \<=2N+R-
* signed inform consent

Exclusion Criteria:

* Vallecula carcinoma

Primary outcomes:
measure: loco-regional control
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Caen
country: France
facility: Centre Francois Baclesse
city: Lyon
country: France
facility: Hôpital de la Croix Rousse
city: Vandoeuvre les Nancy
country: France
facility: Centre Alexis Vautrin
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Stephane Temam
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01939860: A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertension
Lead sponsor: University of Warwick
Sponsor class: OTHER
First posted: 2013-09-11
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypertension is a major health problem, however its control is unsatisfactory. One of the reasons for such a high prevalence of this disease includes poor patient compliance to treatment. Approximately 30 % of newly diagnosed hypertensive patients stop taking their blood pressure medication by six months and 50% by 12 months.

The UK government is keen to encourage community pharmacists to play an active role in participation of services that can improve patient adherence to their medications. The New Medicines Service (NMS) and targeted Medicines Use Reviews (MUR) are established services which fund community pharmacists to review and explain medicine use to patients, with hypertension a common condition for which advice is given within these schemes. Within these schemes, advice is verbal and unstructured, with no specific written information provided on drugs or the disease being treated.

This study aims to determine whether structured information provided to participants verbally and in writing by community pharmacists about blood pressure and current medicine(s) within NMS and targeted MURs will be retained and will be associated with improved hypertension control. Participants will be recruited from people eligible for NMS and MURs and attending community pharmacies.


Eligibility criteria: Inclusion Criteria:

1)18 or over 2) male or female 3) Have been started on any blood pressure medication

Exclusion Criteria:

1)Patients with English language problems

Primary outcomes:
measure: Changes in systolic or diastolic blood pressure
timeFrame: 1 year (trial would be stopped at 26 weeks if it is not possible to recruit any further participants
Secondary outcomes:
measure: change in the knowledge of hypertension
timeFrame: one year(trial would be stopped at 26 weeks if it is not possible to recruit any further participants)
Other outcomes:
Locations:
city: Coventry
country: United Kingdom
facility: J P Goes chemist
Study officials:
References:
Clinical trial NCT01587560: A Comparison Between a Pyrocarbon and a CoCr Shoulder Resurfacing Implant
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Osteoarthritis of the Shoulder
Keywords: Shoulder
Arthroplasty
Pyrocarbon
Randomized controlled trial
Shoulder resurfacing
Lead sponsor: Danderyd Hospital
Sponsor class: OTHER
Collaborators: name: Ascension Orthopedics, Inc.
name: Swedish Shoulder and Elbow Arthroplasty Register
name: Karolinska Institutet
First posted: 2012-04-30
Enrollment: 80
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate fixation to bone and the clinical results following shoulder resurfacing arthroplasty. The study will compare results between an implant made of Cobalt-Chrome(CoCr) and an implant made in pyrocarbon.


Eligibility criteria: Inclusion Criteria:

* Primary or secondary osteoarthritis of the shoulder
* Age 40-75 years
* Patient capable of giving informed consent
* Patient agrees to comply with the study plan

Exclusion Criteria:

* Destruction of the proximal humerus
* Insufficient bone stock
* Deficient rotator cuff or earlier failed surgery of the rotator cuff
* Large muscle defects or insufficient blood supply in the affected arm
* Neuromuscular disorders
* Infection, untreated malignancy or transmittable disease preventing the patient from fulfilling the study
* Patient unwilling to comply with study regulations
* Patient with earlier allergic reaction to pyrocarbon
* Patient with known metastatic disease
* Patient who has been treated with more than 10 mg corticosteroids (e.g. Prednisone) daily within 3 months from surgery.
* Patient participating in other clinical study
* Patient in need of glenoid replacement

Primary outcomes:
measure: Fixation to bone as measured with radiostereometric analysis (RSA)
timeFrame: 24 months
Secondary outcomes:
measure: Clinical results after surgery as measured with EuroQol-5D(EQ-5D), American Shoulder and Elbow Surgeons Score(ASES), Constant score, and Western Ontario Osteoarthritis of the Shoulder index(WOOS)
timeFrame: 24-48 months
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Orthopaedic department, Danderyd Hospital
Study officials:
References:
Clinical trial NCT03810560: Erbium Chromium: YSGG Laser Effect on Surgical Treatment of Chronic Periodontitis
Official title: Microbiological and Clinical Assessments of Erbium Chromium: YSGG Laser as an Adjunctive to Surgical Treatment of Chronic Periodontitis (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Generalized Chronic Periodontitis
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-01-18
Enrollment: 34
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Microbiological and Clinical assessment of Er,Cr:YSGG laser in conjunction to open flap debridement (OFD) in treatment of chronic periodontitis through real time PCR assay for quantification of total bacterial load.

Detailed description: Two groups are randomly allocated (random number generation) by Microsoft excel into two groups :

1. Group (1) Open Flap debridement (OFD) surgery after conventional periodontal therapy (Scaling \&Curettage and root planing) combined by Er,Cr:YSGG Laser assisted pocket therapy (ELAPT) which will be applied to pocket epithelial lining and root surface.
2. Group (2) Open Flap debridement (OFD) surgery after conventional periodontal therapy (Scaling \&Curettage and root planing) will be performed.

Eligibility criteria: Inclusion Criteria:

* Patients are diagnosed to have chronic periodontitis, having infrabony posterior periodontal pocket measuring 5 mm or more.
* female or male.
* 25 - 55 years.
* Medically controlled according to medical coding of review of systems .
* Patient without history of drug administration in last month .

Exclusion criteria:

* Tobacco smoking.
* Pregnancy.
* Patients not follow periodontal hygienic instructions.
* Patients under any medication that affect periodontal healing.
* The presence of any systemic disease that affect periodontal healing.

Primary outcomes:
measure: Clinical Assessment of Plaque index(PI)
timeFrame: 6 months
measure: Clinical Assessment of Gingival index(GI) to assess gingival inflammation. 0: normal gingiva. 1: mild inflammation . 2: moderate inflammation . 3: sever inflammation marked redness and edema and spontaneous bleeding.
timeFrame: 6 months
measure: Clinical Assessment of Probing depth (PD).
timeFrame: 6 months
measure: Clinical Assessment of Clinical attachment level (CAL) .
timeFrame: 6 months
measure: Clinical Assessment of Gingival recession(GR)
timeFrame: 6 months
measure: Clinical Assessment of Modified sulcular bleeding index (MSBI)
timeFrame: 6 months
Secondary outcomes:
measure: Microbiological assessment through real time PCR assay for quantification of total bacterial load by universal probe and primer set (16sr RNA)
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03999060: Trigeminal Brainstem Mapping
Official title: Brainstem Mapping of Nociceptive Trigeminal Input
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Headache Disorders, Primary
Migraine
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2019-06-26
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: To what extent the somatotopy of the 3 branches of the trigeminal nerve (V1,V2,V3) as well as the greater occipital nerve (GON) in the brainstem but also in the thalamus and the insula can be mapped using functional imaging and BOLD in humans is not known but might play an important role in imaging headache diseases. The aim is to map their somatotopy by random stimulation of V1, V2, V3 and the GON with painful electrical input during acquisition of BOLD-fMRI.


Eligibility criteria: Inclusion Criteria:

* healthy
* suitable fo MRI

Exclusion Criteria:

* headache disease
* psychological disorder
* pregnancy
* all exclusion criteria necessary for imaging in a 3 T MRI scanner

Primary outcomes:
measure: Statistical Parametric Map calculated from the fMRI data on brainstem level
timeFrame: through study completion, an average of 9 months
measure: Statistical Parametric Map calculated from the fMRI data in the thalamus
timeFrame: through study completion, an average of 9 months
measure: Statistical Parametric Map calculated from the fMRI data in the insula
timeFrame: through study completion, an average of 9 months
Secondary outcomes:
measure: Statistical Parametric Map calculated from the fMRI data in the cerebellum
timeFrame: through study completion, an average of 9 months
measure: Statistical Parametric Map calculated from the fMRI data in the periaqueductal gray (PAG)
timeFrame: through study completion, an average of 9 months
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: UKE
Study officials:
affiliation: Universitätsklinikum Hamburg-Eppendorf
name: Arne May, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05531760: Predictive Factors of Graft Detachment Following Dmek
Official title: Predictive Factors of Graft Detachment Following Dmek: Retrospective Study About 170 Cases
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fuchs' Endothelial Corneal Dystrophy
Descemet Membrane Endothelial Keratoplasty
Pseudophakic Bullous Keratopathy
Graft Detachment
Lead sponsor: Centre Hospitalier Régional Metz-Thionville
Sponsor class: OTHER
First posted: 2022-09-08
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with fuchs endothelial corneal dystrophy and patients with pseudophakic bullous keratopathies requiring corneal transplantation

Brief summary: The aim of this study was to identify the predictive factors of graft detachment after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. This retrospective study was conducted on patients aged 18 years, with Fuchs' dystrophy (FECD) or pseudophakic bullous keratopathy (PBK), who were scheduled for DMEK or triple-DMEK (combined phacoemulsification and DMEK surgery). Patients with a history of surgery other than cataract surgery were excluded. The study was conducted between 2014 and 2022 and follow-up was for 3 months. The characteristics of patients with and without graft detachment following surgery were compared using logistic regression.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years of age with DMEK surgery

Exclusion Criteria:

* all associated eye surgery other than cataract surgery
* all existing anterior segment anomalies

Primary outcomes:
measure: Appearence of the graft on anterior segment optical coherence tomography (AS OCT) examination
timeFrame: up to 3 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Metz
country: France
facility: CHR Metz-Thionville/Hopital de Mercy
Study officials:
affiliation: CHR Metz Thionville Hopital de Mercy
name: Jean-Marc PERONE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01072760: Kirschner Wire and Pull-out Wire Fixation for the Treatment of Bony Mallet Finger
Official title: Kirschner Wire and Pull-out Wire Fixation for the Treatment of Bony Mallet Finger
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bony Mallet Finger
Keywords: Mallet finger
extensor tendon
Kirschner wire
Fracture Fixation
Lead sponsor: The Second Hospital of Qinhuangdao
Sponsor class: OTHER
First posted: 2010-02-22
Enrollment: 54
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this report is to describe a new surgical technique for the treatment of bony mallet finger which involves the application of both Kirschner wire and pull-out wire fixation. It is believed to decrease the risk of the complications.

Detailed description: From May 2003 to December 2008, we used Kirschner wire and pull-out wire fixation to carry out 54 closed bony mallet finger in 54 patients. The bony mallet finger was applicated both Kirschner wire and pull-out wire fixation.

Eligibility criteria: Inclusion Criteria:

1. bony mallet finger;
2. patient had failed trials of nonsurgical treatment;
3. fracture involving more than 1/3 of the joint surface;
4. fragment displacement or subluxation of the DIP joint.

Exclusion Criteria:

1. tendinous mallet finger;
2. success of nonsurgical treatment;
3. comminuted fracture;
4. fracture involving at or less than 1/3 of the joint surface which could be successfully replaced with nonsurgical treatment.

Primary outcomes:
measure: The digits were assessed for skin necrosis, skin breakdown, infection.
timeFrame: 15 days
Secondary outcomes:
measure: The patients rated their pain experience by a visual analogue scale. The results were graded by Crawford's criteria.
timeFrame: 1 year
Other outcomes:
Locations:
city: Qinhuangdao
country: China
facility: The second hospital of Qinhuangdao
state: Hebei
Study officials:
affiliation: The Second Hospital of Qinhuangdao
name: Sumin Wen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee YH, Kim JY, Chung MS, Baek GH, Gong HS, Lee SK. Two extension block Kirschner wire technique for mallet finger fractures. J Bone Joint Surg Br. 2009 Nov;91(11):1478-81. doi: 10.1302/0301-620X.91B11.22478.
Clinical trial NCT01345760: Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer
Official title: Expression Levels of RNA-induced Silencing Complex (RISC) Components TARBP1, TARBP2, Argonaute-1, Argonaute-2, PACT and Microprocessor Complex Component DGCR8 in Epithelial Skin Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Cancer
Keywords: Basal Cell Carcinoma
Squamous Cell Carcinoma
Actinic Keratosis
microRNA
Dicer
Drosha
RISC
microprocessor complex
Argonaute
DGCR8
TARBP
Lead sponsor: Ruhr University of Bochum
Sponsor class: OTHER
First posted: 2011-05-02
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with epithelial skin cancer and pre-malignant stages

Brief summary: MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of the microprocessor complex subunit DGCR8 and the RISC components TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT in epithelial skin cancer and its premalignant stage.

Detailed description: Patients with premalignant actinic keratoses, basal cell carcinomas and squamous cell carcinomas were included in the study. Punch biopsies were harvested from the center of the tumors, from sites of healthy skin and a healthy control group. DGCR8, TARBP1, TARBP2, argonaute-1, argonaute-2 and PACT mRNA expression levels were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

Eligibility criteria: Inclusion Criteria:

* epithelial skin cancer

Exclusion Criteria:

* other known previous malignancies

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bochum
country: Germany
facility: Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
state: NRW
Study officials:
affiliation: Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
name: Falk G Bechara, PD Dr.
role: STUDY_DIRECTOR
References:
citation: Sand M, Skrygan M, Georgas D, Arenz C, Gambichler T, Sand D, Altmeyer P, Bechara FG. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog. 2012 Nov;51(11):916-22. doi: 10.1002/mc.20861. Epub 2011 Oct 24.